Naloxone shortage goes national in wave of opioid overdose
Public trust in a federal access program for the overdose drug Naloxone has been shaken after more than a year of shortages ...
Inquirer on MSN3h
World’s first anti-depression nasal spray receives FDA approval
The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more potent ...
BioSpace18h
GH’s Inhaled Psychedelic Succeeds in Mid-Stage Depression Trial
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...
Padagis Naloxone Now the Lowest Priced Opioid Overdose Treatment Available on Amazon
Padagis®, a leading generic manufacturer, announced today it is lowering the price of its over-the-counter (OTC) 4 mg ...
thecardiologyadvisor.com20h
Nasal Spray Formulation of Bumetanide Under FDA Review
The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.